Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 60

Cited In for PubMed (Select 18253977)

1.

Effect of the adult pneumococcal polysaccharide vaccine on cardiovascular disease: a systematic review and meta-analysis.

Ren S, Newby D, Li SC, Walkom E, Miller P, Hure A, Attia J.

Open Heart. 2015 Jun 26;2(1):e000247. doi: 10.1136/openhrt-2015-000247. eCollection 2015. Review.

2.

Quantitative and Qualitative Antibody Responses to Immunization With the Pneumococcal Polysaccharide Vaccine in HIV-Infected Patients After Initiation of Antiretroviral Treatment: Results From a Randomized Clinical Trial.

Rodriguez-Barradas MC, Serpa JA, Munjal I, Mendoza D, Rueda AM, Mushtaq M, Pirofski LA.

J Infect Dis. 2015 Jun 1;211(11):1703-11. doi: 10.1093/infdis/jiu819. Epub 2014 Dec 23.

PMID:
25538270
3.

Open-label trial of immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults ≥ 50 years of age in Mexico.

Tinoco JC, Juergens C, Ruiz Palacios GM, Vazquez-Narvaez J, Enkerlin-Pauwells HL, Sundaraiyer V, Pathirana S, Kalinina E, Gruber WC, Scott DA, Schmoele-Thoma B.

Clin Vaccine Immunol. 2015 Feb;22(2):185-92. doi: 10.1128/CVI.00711-14. Epub 2014 Dec 10.

PMID:
25499011
4.

How many individuals with asthma need to be vaccinated to prevent one case of invasive pneumococcal disease?

Okapuu JM, Chétrit E, Lefebvre B, Quach C.

Can J Infect Dis Med Microbiol. 2014 May;25(3):147-50.

5.

Microbial aetiology, outcomes, and costs of hospitalisation for community-acquired pneumonia; an observational analysis.

Spoorenberg SM, Bos WJ, Heijligenberg R, Voorn PG, Grutters JC, Rijkers GT, van de Garde EM.

BMC Infect Dis. 2014 Jun 17;14:335. doi: 10.1186/1471-2334-14-335.

6.

A randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly.

Macintyre CR, Ridda I, Gao Z, Moa AM, McIntyre PB, Sullivan JS, Jones TR, Hayen A, Lindley RI.

PLoS One. 2014 Apr 23;9(4):e94578. doi: 10.1371/journal.pone.0094578. eCollection 2014.

7.

Role of pneumococcal vaccination in prevention of pneumococcal disease among adults in Singapore.

Eng P, Lim LH, Loo CM, Low JA, Tan C, Tan EK, Wong SY, Setia S.

Int J Gen Med. 2014 Mar 31;7:179-91. doi: 10.2147/IJGM.S54963. eCollection 2014. Review.

8.

Cost-effectiveness of pneumococcal vaccines for adults in the United States.

Chen J, O'Brien MA, Yang HK, Grabenstein JD, Dasbach EJ.

Adv Ther. 2014 Apr;31(4):392-409. doi: 10.1007/s12325-014-0115-y. Epub 2014 Apr 10.

9.

Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia.

Ordóñez JE, Orozco JJ.

BMC Infect Dis. 2014 Mar 28;14:172. doi: 10.1186/1471-2334-14-172.

10.

Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults.

Pauksens K, Nilsson AC, Caubet M, Pascal TG, Van Belle P, Poolman JT, Vandepapelière PG, Verlant V, Vink PE.

Clin Vaccine Immunol. 2014 May;21(5):651-60. doi: 10.1128/CVI.00807-13. Epub 2014 Mar 5.

11.

Pneumococcal vaccination rates in adults in Germany: an analysis of statutory health insurance data on more than 850,000 individuals.

Theidel U, Kuhlmann A, Braem A.

Dtsch Arztebl Int. 2013 Nov 1;110(44):743-50. doi: 10.3238/arztebl.2013.0743.

12.

Adult immunization with 13-valent pneumococcal vaccine in Campania region, South Italy: an economic evaluation.

Liguori G, Parlato A, Zamparelli AS, Belfiore P, Gallé F, Di Onofrio V, Riganti C, Zamparelli B; Società Italiana di Health Horizon Scanning (SIHHS).

Hum Vaccin Immunother. 2014;10(2):492-7. doi: 10.4161/hv.26888. Epub 2013 Nov 1.

13.

Risk factors for community-acquired pneumonia in adults in Europe: a literature review.

Torres A, Peetermans WE, Viegi G, Blasi F.

Thorax. 2013 Nov;68(11):1057-65. doi: 10.1136/thoraxjnl-2013-204282. Review.

14.

Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults.

Smith KJ, Nowalk MP, Raymund M, Zimmerman RK.

Vaccine. 2013 Aug 20;31(37):3950-6. doi: 10.1016/j.vaccine.2013.06.037. Epub 2013 Jun 24.

15.

Modifiable risk factors for pneumonia requiring hospitalization of community-dwelling older adults: the Health, Aging, and Body Composition Study.

Juthani-Mehta M, De Rekeneire N, Allore H, Chen S, O'Leary JR, Bauer DC, Harris TB, Newman AB, Yende S, Weyant RJ, Kritchevsky S, Quagliarello V; Health ABC Study.

J Am Geriatr Soc. 2013 Jul;61(7):1111-8. doi: 10.1111/jgs.12325. Epub 2013 Jun 17.

16.

Assessment of vaccine candidates for persons aged 50 and older: a review.

Eilers R, Krabbe PF, van Essen TG, Suijkerbuijk A, van Lier A, de Melker HE.

BMC Geriatr. 2013 Apr 15;13:32. doi: 10.1186/1471-2318-13-32. Review.

17.

Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model.

Pradas R, Gil de Miguel A, Álvaro A, Gil-Prieto R, Lorente R, Méndez C, Guijarro P, Antoñanzas F.

BMC Infect Dis. 2013 Apr 11;13:175. doi: 10.1186/1471-2334-13-175.

18.

The immune response to pneumococcal polysaccharides 14 and 23F among elderly individuals consists predominantly of switched memory B cells.

Leggat DJ, Thompson RS, Khaskhely NM, Iyer AS, Westerink MA.

J Infect Dis. 2013 Jul;208(1):101-8. doi: 10.1093/infdis/jit139. Epub 2013 Apr 1.

19.

Cost-effectiveness of a program to eliminate disparities in pneumococcal vaccination rates in elderly minority populations: an exploratory analysis.

Michaelidis CI, Zimmerman RK, Nowalk MP, Smith KJ.

Value Health. 2013 Mar-Apr;16(2):311-7. doi: 10.1016/j.jval.2012.11.009.

20.

Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults.

Smith KJ, Wateska AR, Nowalk MP, Raymund M, Lee BY, Zimmerman RK.

Am J Prev Med. 2013 Apr;44(4):373-81. doi: 10.1016/j.amepre.2012.11.035.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk